TRAVERE THERAPEUTICS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TRAVERE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $2.83M, a 52.48% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $456.00K, a 45.22% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $1.65M, a 24.70% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $362.00K, a 23.97% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $4.18M, a 17.25% increase from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $3.57M, a 26.52% decline from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $4.85M, a 13.95% increase from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $4.26M, a 41.40% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $2.83M 10-Q · filed 2026-08-04 | $5.30M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $456.00K 10-Q · filed 2026-05-04 | $4.32M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $4.18M 10-K · filed 2026-02-19 |
| 2025-09-30 | $362.00K 10-Q · filed 2025-10-30 | $3.85M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.85M 10-Q · filed 2026-08-04 | $3.78M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $314.00K 10-Q · filed 2026-05-04 | $3.54M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.57M 10-K · filed 2026-02-19 |
| 2024-09-30 | $292.00K 10-Q · filed 2025-10-30 | $3.55M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $1.61M 10-Q · filed 2025-08-06 | $3.68M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $338.00K 10-Q · filed 2025-05-01 | $4.75M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $4.85M 10-K · filed 2026-02-19 |
| 2023-09-30 | $418.00K 10-Q · filed 2024-10-31 | $5.38M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $2.69M 10-Q · filed 2024-08-01 | $5.32M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $439.00K 10-Q · filed 2023-05-04 | $4.45M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $4.26M 10-K · filed 2025-02-21 |
| 2022-09-30 | $362.00K 10-Q · filed 2022-10-27 | $3.50M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $1.81M 10-Q · filed 2023-08-03 | $3.37M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $251.00K 10-Q · filed 2023-05-04 | $3.05M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $3.01M 10-K · filed 2024-02-20 |
| 2021-09-30 | $228.00K 10-Q · filed 2022-10-27 | $3.12M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $1.50M 10-Q · filed 2022-08-04 | $3.15M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $214.00K 10-Q · filed 2022-05-05 | $2.95M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $2.93M 10-K · filed 2023-02-23 |
| 2020-09-30 | $261.00K 10-Q · filed 2021-10-29 | $2.68M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $1.29M 10-Q · filed 2021-07-29 | $2.58M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $196.00K 10-Q · filed 2021-05-06 | $2.47M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $932.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.44M 10-K · filed 2022-02-24 |
| 2019-09-30 | $162.00K 10-Q · filed 2020-11-05 | $2.58M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $1.18M 10-Q · filed 2020-07-31 | $2.58M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $175.00K 10-Q · filed 2020-05-11 | $2.33M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $2.27M 10-K · filed 2021-03-01 |
| 2018-09-30 | $154.00K 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $928.00K 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $116.00K 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $893.00K 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |